Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Publication charge
Books and Events
Books
Events
ORIGINAL PAPER
Clinical and laboratory pattern of patients with systemic lupus erythematosus seropositive for rheumatoid factor
1
Bogomolets National Medical University, Ukraine
2
State Institution National Scientific Center Institute of Cardiology, Clinical and Regenerative Medicine named after Academician M.D. Strazhesko of the National Academy of Medical Sciences of Ukraine, Ukraine
Submission date: 2024-06-08
Final revision date: 2024-07-24
Acceptance date: 2024-08-26
Publication date: 2024-09-16
Corresponding author
Vitalii Dubas
State Institution National Scientific Center Institute of Cardiology, Clinical and Regenerative Medicine named after Academician M.D. Strazhesko of the National Academy of Medical Sciences of Ukraine, 5 Svyatoslava Khorobroho St., 03680, Kyiv, Ukraine
State Institution National Scientific Center Institute of Cardiology, Clinical and Regenerative Medicine named after Academician M.D. Strazhesko of the National Academy of Medical Sciences of Ukraine, 5 Svyatoslava Khorobroho St., 03680, Kyiv, Ukraine
Reumatologia 2024;62(4):226-234
KEYWORDS
TOPICS
SLE, Sjögren syndrome and APS - aetiology, pathogenesis, clinical features and treatmentDiagnostics and imaging in rheumatic diseases
ABSTRACT
Introduction:
The aim of the study was to investigate the associations between the presence and level of rheumatoid factor (RF) in the blood serum and the clinical and laboratory characteristics of patients with systemic lupus erythematosus (SLE).
Material and methods:
This retrospective tricentric cross-sectional study analyzed a Ukrainian contingent of SLE patients. Medical records of 495 patients were evaluated. Rheumatoid factor serum concentration was tested in 206 of them (41.6%) using turbidimetry technique. Clinical manifestations, routine laboratory parameters, specific immunological tests, disease activity (SLEDAI-2K), and damage indices (SLICC/ACR DI) were evaluated.
Results:
Our study revealed that RF was elevated in 27.7% of patients. The RF-positive patients experienced a longer delay in SLE diagnosis (2.0 vs. 0.5 years, p = 0.046), less frequent kidney involvement (42.1% vs. 59.4%, p = 0.045) and fever (42.1% vs. 59.2%, p = 0.046), and more frequent lymphadenopathy (59.6% vs. 42.3%, p = 0.039) compared to RF-negative patients. Patients with RF positivity had higher levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and antinuclear antibody (ANA) titer, and were more frequently positive for antibodies to Ro/SSA and La/SSB. Rheumatoid factor concentration directly correlated with CRP (r = 0.318; p < 0.01) and ESR (r = 0.228; p = 0.04) levels. However, no associations were found between RF levels and SLEDAI-2K, joint involvement frequency, SLICC/ACR DI or drug therapy content. Univariate logistic regression analysis showed that RF positivity was independently associated with lymphadenopathy, presence of anti-Ro/SSA and anti-La/SSB antibodies, and negatively associated with kidney involvement.
Conclusions:
In RF-seropositive SLE patients (approximately 28%), the diagnosis is established later compared to RF-seronegative ones; kidney involvement and fever are less common, while lymphadenopathy develops more frequently. Rheumatoid factor seropositivity is associated with higher levels of ESR, CRP, ANA, and the presence of antibodies to Ro/SSA and La/SSB. According to the results of univariate logistic regression analysis, an independent association with RF positivity was confirmed only for kidney involvement, lymphadenopathy, and antibodies to Ro/SSA and La/SSB.
The aim of the study was to investigate the associations between the presence and level of rheumatoid factor (RF) in the blood serum and the clinical and laboratory characteristics of patients with systemic lupus erythematosus (SLE).
Material and methods:
This retrospective tricentric cross-sectional study analyzed a Ukrainian contingent of SLE patients. Medical records of 495 patients were evaluated. Rheumatoid factor serum concentration was tested in 206 of them (41.6%) using turbidimetry technique. Clinical manifestations, routine laboratory parameters, specific immunological tests, disease activity (SLEDAI-2K), and damage indices (SLICC/ACR DI) were evaluated.
Results:
Our study revealed that RF was elevated in 27.7% of patients. The RF-positive patients experienced a longer delay in SLE diagnosis (2.0 vs. 0.5 years, p = 0.046), less frequent kidney involvement (42.1% vs. 59.4%, p = 0.045) and fever (42.1% vs. 59.2%, p = 0.046), and more frequent lymphadenopathy (59.6% vs. 42.3%, p = 0.039) compared to RF-negative patients. Patients with RF positivity had higher levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and antinuclear antibody (ANA) titer, and were more frequently positive for antibodies to Ro/SSA and La/SSB. Rheumatoid factor concentration directly correlated with CRP (r = 0.318; p < 0.01) and ESR (r = 0.228; p = 0.04) levels. However, no associations were found between RF levels and SLEDAI-2K, joint involvement frequency, SLICC/ACR DI or drug therapy content. Univariate logistic regression analysis showed that RF positivity was independently associated with lymphadenopathy, presence of anti-Ro/SSA and anti-La/SSB antibodies, and negatively associated with kidney involvement.
Conclusions:
In RF-seropositive SLE patients (approximately 28%), the diagnosis is established later compared to RF-seronegative ones; kidney involvement and fever are less common, while lymphadenopathy develops more frequently. Rheumatoid factor seropositivity is associated with higher levels of ESR, CRP, ANA, and the presence of antibodies to Ro/SSA and La/SSB. According to the results of univariate logistic regression analysis, an independent association with RF positivity was confirmed only for kidney involvement, lymphadenopathy, and antibodies to Ro/SSA and La/SSB.
REFERENCES (21)
1.
Soltys A, Axford J, Sutton B. Rheumatoid factors: Where are we now? Ann Rheum Dis 1997; 56: 285–286, DOI: 10.1136/ard. 56.5.285.
2.
Tiwari V, Jandu JS, Bergman MJ. Rheumatoid factor. In: StatPearls. StatPearls Publishing, Treasure Island (FL) 2024.
3.
Garate DG, Yucra DD, Balcazar R, et al. Rheumatoid factor in patients with systemic lupus erythematosus. Lupus Sci Med 2019; 6: e000073, DOI: 10.1136/lupus-2019-lsm.73.
4.
Witte T, Hartung K, Sachse C, et al. Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. Rheumatol Int 2000; 19: 107–111, DOI: 10.1007/s002960050112.
5.
Fedrigo A, dos Santos TAFG, Nisihara R, Skare T. The lupus patient with positive rheumatoid factor. Lupus 2018; 27: 1368–1373, DOI: 10.1177/0961203318759607.
6.
Tarkowski A, Westberg G. Rheumatoid factor isotypes and renal disease in systemic lupus erythematosus. Scand J Rheumatol 1987; 16: 309–312, DOI: 10.3109/03009748709102501.
7.
Skare TL, Silva MB, Holler AP, Chavez PA. Protective role of rheumatoid factor in lupus nephritis. Clin Exp Rheumatol 2009; 27: 895.
8.
Spadaro A, Riccieri V, Terracina S, et al. Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus. Lupus 2000; 9: 56–60, DOI: 10.1177/ 096120330000900110.
9.
Popescu C, Zofotă S, Bojincă V, Ionescu R. The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus. Rom J Intern Med 2013; 51: 179–187.
10.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277, DOI: 10.1002/art.1780251101.
11.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725, DOI: 10.1002/art.1780400928.
12.
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686, DOI: 10.1002/art.34473.
13.
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019; 71: 1400–1412, DOI: 10.1002/art. 40930.
14.
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.
15.
Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369, DOI: 10.1002/art.1780390303.
16.
Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521–530, DOI: 10.1111/j.1523-1755.2004.00443.x.
17.
Bouchedoub Y, Djenouhat K, Rachedi N, et al. Association of markers of rheumatoid arthritis in lupus. Is it a rhupus? Ann Biol Clin (Paris) 2020; 78: 201–205, DOI: 10.1684/abc. 2020.1518.
18.
Watanabe S, Gono T, Nishina K, et al. Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibody-associated vasculitis. BMC Immunol 2017; 18: 53, DOI: 10.1186/s12865-017-0234-8.
19.
Carbonell-Bobadilla N, Soto-Fajardo C, Amezcua-Guerra LM, et al. Patients with seronegative rheumatoid arthritis have a different phenotype than seropositive patients: A clinical and ultrasound study. Front Med (Lausanne) 2022; 9: 978351, DOI: 10.3389/fmed.2022.978351.
20.
Xiao CY, Pan YF, Gu JR, Wu YQ, Huang JL, Yu BY. Correlation between rheumatoid factor and activity or severity of rheumatoid arthritis. J Clin Rehabil Tissue Eng Res 2008; 12: 9193–9196.
21.
Maślińska M, Mańczak M, Kwiatkowska B. Usefulness of rheumatoid factor as an immunological and prognostic marker in PSS patients. Clin Rheumatol 2019; 38: 1301–1307, DOI: 10.1007/s10067-019-04438-z.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
